[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-417323-105":59,"doc-detail-417323-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","outcome-of-ruthenium-106-brachytherapy-for-uveal-melanoma-and-retinal-vascular-tumors-a-retrospective-study","Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors - A Retrospective Study","","This retrospective case-series evaluated the efficacy and safety of Ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma and retinal vascular tumors. Patients treated at Torfeh Medical Center between March 2016 and March 2022 were assessed using SPSS, with tumor regression as the primary endpoint and complications as secondary outcomes. Among 80 patients, regression occurred in 74.5% of melanoma and 100% of vasoproliferative tumor/retinal capillary hemangioma. Complications included radiation retinopathy and cataract formation, with recurrence rates of 16.4% and 7.7%, respectively.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcome-of-ruthenium-106-brachytherapy-for-uveal-melanoma-and-retinal-vascular-tumors-a-retrospective-study/417323/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcome-of-ruthenium-106-brachytherapy-for-uveal-melanoma-and-retinal-vascular-tumors-a-retrospective-study/417323.png","ImageObject",300,407,{"name":92,"@type":93},"ahduag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary purpose of this study?","Question",{"text":113,"@type":114},"To evaluate the efficacy and safety of Ru-106 plaque brachytherapy in patients with uveal melanoma and retinal vascular tumors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were treatment outcomes and complications assessed?",{"text":118,"@type":114},"Clinical data on tumor features and treatment details were analyzed using SPSS, with tumor regression as the primary outcome and complications as secondary outcomes.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main results regarding tumor regression and recurrence?",{"text":122,"@type":114},"Tumor regression was seen in 74.5% of melanoma cases and 100% of vasoproliferative tumor/retinal capillary hemangioma cases. Recurrence rates were 16.4% in melanoma and 7.7% in VPT/RCH.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},417323,1790797141,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3985747870414,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","| Original Article |\n| --- |\n|  |\n\nOutcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study  \nSaeed Karimi1,2*, Sadra Ashrafi1*, Seyyed Morteza Hosseini Imeni1, Zahra Siavashpour3  \n1Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 3Department of Radiation Oncology, Shohada‑e Tajrish  \nEducational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n*The first and second authors contributed equally to this work  \nAbstract  \nPurpose: To evaluate the efficacy and safety of brachytherapy in patients with uveal melanoma and retinal vascular tumors.  \nMethods: Patients who received Ruthenium-106 (Ru-106) plaque brachytherapy atthe Torfeh Medical Center between March 2016 and March 2022 were examined in this retrospective case-series. We collected clinical data on tumor features, treatment details, and patient outcomes. These data were analyzed using SPSS software. Tumor regression was the primary outcome that was monitored, with complications being evaluated as secondary outcomes.  \nResults: Of the 80 patients, 55 had melanoma, 21 had vasoproliferative tumor (VPT), and 4 had retinal capillary hemangioma (RCH) . Tumor regression was observed in 74.5% of melanoma cases and 100% of VPT/RCH cases. Significant relationships were found between tumor characteristics, such as thickness and dose rate at the apex, and treatment outcomes. Complications included radiation retinopathy and cataract formation, with recurrence rates of 16.4% in melanoma and 7.7% in VPT/RCH.  \nConclusions: Ru-106 plaque brachytherapy is effective in treating various intraocular tumors, particularly VPT/RCH. Tumor thickness significantly influences treatment outcomes, emphasizing the need for tailored approaches in brachytherapy planning. However, small sample sizes for specific tumor types limited the generalization of the outcomes. Future research should focus on refining techniques and mitigating complications to improve patient outcomes in ocular oncology.  \nKeywords: Brachytherapy, Intraocular tumor, Outcome  \nAddress for correspondence: Zahra Siavashpour, Department of Radiation Oncology, Shohada‑e Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Tajrish Square, Shahrdari Street, Tehran, Iran.  \nE‑mail: [zahrasiavashpour@gmail.com](zahrasiavashpour@gmail.com)  \nSubmitted: 18‑Nov‑2024; Revised: 06‑Oct‑2025; Accepted: 17‑Oct‑2025; Published: 19‑Dec‑2025  \nIntroductIon  \nOcular tumors, comprising both primary and metastatic cancers, represent a significant health burden due to their potential to threaten vision and life. 1,2 According to a global analysis of cancer registries, the age-standardized rates of eye cancer incidence and mortality in 2020 were 0.49 and 0.08/100,000 globally, respectively.1 A study utilizing data from the Iranian National Population-based Cancer Registry revealed that the overall incidence proportion of ocular cancers  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code:\u003Cbr>| Website:\u003Cbr>[https://journals.lww.com/joco](https://journals.lww.com/joco) |\n|  | DOI:\u003Cbr>10.4103/joco.joco_248_24 |\n\nin Iran from 2004 to 2016 was 16.04/100,000 population. Specifically, this registry documented a 6% prevalence of intraocular tumors among patients with cancer.3  \nPlaque brachytherapy has long been recognized as a pivotal treatment modality for medium-sized uveal melanoma, marking its significance in the realm of ocular oncology.4,5 This technique harnesses the power of localized radiation,  \nThis is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cite","cbCaibaGjxiACLK9","https://ap.wps.com/l/cbCaibaGjxiACLK9","pdf",1886217,"English","# Abstract\n# Introduction\n## Ocular tumor burden and epidemiology\n## Plaque brachytherapy rationale and Ru-106 role","[{\"question\":\"What was the primary purpose of this study?\",\"answer\":\"To evaluate the efficacy and safety of Ru-106 plaque brachytherapy in patients with uveal melanoma and retinal vascular tumors.\"},{\"question\":\"How were treatment outcomes and complications assessed?\",\"answer\":\"Clinical data on tumor features and treatment details were analyzed using SPSS, with tumor regression as the primary outcome and complications as secondary outcomes.\"},{\"question\":\"What were the main results regarding tumor regression and recurrence?\",\"answer\":\"Tumor regression was seen in 74.5% of melanoma cases and 100% of vasoproliferative tumor/retinal capillary hemangioma cases. Recurrence rates were 16.4% in melanoma and 7.7% in VPT/RCH.\"}]","Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors - A Retrospective Study | PDF",1790608856,23]